



## MCDA (Multi-Criteria Decision Analysis) – Polish experience and results of Poland MCDA data on late stage oncology

Aleksandra Zawodnik

MSc Pharm, PhD Candidate

Department of Experimental and Clinical Pharmacology,  
Medical University of Warsaw, Warsaw, Poland

### **PAST – PRESENT – FUTURE of MCDA in Poland**

- Ordinance by National Health Fund (2007)
- Economic Council of MoH (2012)
- Reimbursement decision criteria (2011)
- IOWISZ (Evaluation Instrument of Investment Motions in Health Care, 2016)
- The algorithm assessing the value of new anticancer drugs — the proposal of the Polish Society of Clinical Oncology and Polish Oncological Society (2015)

# Poland MCDM data on oncology


## Results

### Polish MCDM data on oncology


- Performed June-October 2017 r.



4	• Payer
6	• Pharma
1	• Patient
3	• Public
1	• Politician
5	• Pharmacists
3	• Physicians



### Poland median weights on all criteria by all (7P) representatives






### Poland Pharma on all criteria












## Combined data for oncology

### Results

# Combined data for oncology




## Pharma on all criteria for oncology







## Payer on all criteria for oncology




## Physician on all criteria for oncology




## Pharmacist on all criteria for oncology




## Patient on all criteria for oncology



## Public on all criteria for oncology



## Median on all criteria from all representatives from all included countries for oncology



*Thank You very much for attention!*

contact: [aleksandra.zawodnik@gmail.com](mailto:aleksandra.zawodnik@gmail.com)